Imaging equipment and pharmaceutical manufacturers are waitingwith bated breath for the unveiling of revised Food and Drug Administrationguidelines on industry participation in medical meetings. Withoutmajor revisions, the FDA proposal would restrict
Imaging equipment and pharmaceutical manufacturers are waitingwith bated breath for the unveiling of revised Food and Drug Administrationguidelines on industry participation in medical meetings. Withoutmajor revisions, the FDA proposal would restrict equipment exhibitsand industry sponsorship of medical meetings (SCAN 5/20/92).
The FDA has been in the rewrite stages since March after receivingmore than 200 comments on the proposal, according to Mike Shafer,an FDA press liaison.
The guidelines were prompted by concerns about abuses in industry-fundedcontinuing medical education programs. The FDA, which regulatespromotion of medical devices, devised the guidelines to definephysician education versus product promotion.
Initially aimed at pharmaceutical companies, the revised guidelinesare expected to target imaging equipment manufacturers as well,according to Robin Wiley, assistant for legislative affairs atthe National Electrical Manufacturers Association.
The policy would permit industry sponsors to continue to fundCME programs, specialty society meetings, medical journals, videotapesand computer software. But companies must not suggest speakersor topics, or influence content in any way. Nor would they beallowed to distribute materials about products that detail unapproveduses.
A component of the proposal would also restrict exhibits ofunapproved devices at medical meetings. A new FDA branch has alreadybeen established to monitor compliance, according to Wiley. Firmdetails about the new policy remain elusive, however.
"There have been a lot of rumors floating around but wehave yet to see new guidelines coming from the FDA," shesaid. "We do know they are working on ways to include devicemanufacturers in the guidelines."
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.